Compare SNGX & MYSZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | MYSZ |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 2.2M |
| IPO Year | 2006 | 2017 |
| Metric | SNGX | MYSZ |
|---|---|---|
| Price | $0.37 | $1.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 204.3K | ★ 674.9K |
| Earning Date | 05-08-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.03 | ★ 57.40 |
| EPS | ★ N/A | N/A |
| Revenue | $119,371.00 | ★ $142,000.00 |
| Revenue This Year | N/A | $41.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 125.40 |
| 52 Week Low | $0.28 | $0.33 |
| 52 Week High | $1.97 | $4.28 |
| Indicator | SNGX | MYSZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 44.81 |
| Support Level | $0.35 | $0.47 |
| Resistance Level | $0.41 | $2.60 |
| Average True Range (ATR) | 0.01 | 0.24 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 33.11 | 3.48 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.